Log in to save to my catalogue

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast...

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_582b84ec644248bbb6fb9af5a9be5532

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

About this item

Full title

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

Publisher

England: eLife Sciences Publications Ltd

Journal title

eLife, 2018-11, Vol.7

Language

English

Formats

Publication information

Publisher

England: eLife Sciences Publications Ltd

More information

Scope and Contents

Contents

Acquired resistance to endocrine therapy remains a significant clinical burden for breast cancer patients. Somatic mutations in the
(estrogen receptor alpha (ERα)) gene ligand-binding domain (LBD) represent a recognized mechanism of acquired resistance. Antiestrogens with improved efficacy versus tamoxifen might overcome the resistant phenotype...

Alternative Titles

Full title

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_582b84ec644248bbb6fb9af5a9be5532

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_582b84ec644248bbb6fb9af5a9be5532

Other Identifiers

ISSN

2050-084X

E-ISSN

2050-084X

DOI

10.7554/eLife.37161

How to access this item